ArriVent BioPharma (AVBP) Other financing activities (2023 - 2026)
ArriVent BioPharma (AVBP) reported Other financing activities of $149000.0 for Q1 2026, down 49.15% on a YoY basis from $293000.0 in Q1 2025, and up 77.38% sequentially from $84000.0 in Q4 2025.
ArriVent BioPharma (AVBP) Other financing activities (2023 - 2026) Analysis & Trends
ArriVent BioPharma (AVBP) has 4 years of Other financing activities data on file, last reported at $149000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other financing activities fell 49.15% year-over-year to $149000.0; the trailing twelve-month figure through Mar 2026 stood at $358000.0 (down 61.21% YoY), and the FY2025 full-year result was $502000.0, down 20.44% from the prior year.
- Other financing activities improved to $149000.0 in Q1 2026, from $84000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $531000.0 in Q3 2024 to a low of $1000.0 in Q1 2024.
- A 4-year average of $125846.2 and a median of $55000.0 in 2024 frame the typical range for Other financing activities.
- Across the five-year window, Other financing activities sank 96.15% in 2024 and soared 29200.0% in 2025, its largest moves.
- Tracing AVBP's Other financing activities over 4 years: stood at $285000.0 in 2023, then tumbled by 80.7% to $55000.0 in 2024, then surged by 52.73% to $84000.0 in 2025, then surged by 77.38% to $149000.0 in 2026.
- Business Quant data shows AVBP's Other financing activities at $149000.0 in Q1 2026, $84000.0 in Q4 2025, and $49000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | ArriVent BioPharma | 1.42 Bn | 1.42 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 149,000.00 |
| Mar 31, 2026 | 149,000.00 |
| Dec 31, 2025 | 84,000.00 |
| Dec 31, 2025 | 84,000.00 |
| Sep 30, 2025 | 49,000.00 |
| Sep 30, 2025 | 49,000.00 |
| Jun 30, 2025 | 76,000.00 |
| Jun 30, 2025 | 76,000.00 |
| Mar 31, 2025 | 293,000.00 |
| Mar 31, 2025 | 293,000.00 |
| Dec 31, 2024 | 55,000.00 |
| Dec 31, 2024 | 55,000.00 |
| Sep 30, 2024 | 531,000.00 |
| Sep 30, 2024 | 531,000.00 |
| Jun 30, 2024 | 44,000.00 |
| Jun 30, 2024 | 44,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Dec 31, 2023 | 285,000.00 |
| Dec 31, 2023 | 285,000.00 |